← Leaderboards
Eduardo Davila
University Of Colorado Denver
$8,435,659
Attributed
$10,215,137
Total exposure
17
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,215,137 · 15
VA$0 · 2
By mechanism
R01$5,316,497 · 4
R25$2,239,690 · 3
T32$1,480,205 · 1
P20$1,053,203 · 6
P30$125,542 · 1
I01$0 · 2
Top collaborators
- Antonio Jimeno6 shared
- Toni M. Antalis2 shared
- Michael D Kalos2 shared
- Aaron P Rapoport2 shared
- Terry B. Rogers2 shared
- Aimee Bernard1 shared
- Meredith A Tennis1 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Antonio Jimeno$15,496,689
- Edward Abraham$8,831,231
- Meredith A Tennis$3,445,078
- Aimee Bernard$123,188
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorCellsIn VivoSignal TransductionMolecularT-LymphocyteMelanomaIn VitroMalignant NeoplasmsInsightToll-Like ReceptorsNeoplastic CellResponseMediatingTumor ImmunityBaseImmunotherapyReceptorT Cell ResponseTumor AntigensPreventCancer ImmunotherapyNovel StrategiesLigands
Grant awards (47)
Expanding the tumor antigen landscape and maintaining APCs in a T cell-activating state to restore tumor immunity$473,680
R01 · FY2025 · CA · contact PI
Students and Teachers Achieving Cancer Research Experiences Together (START) Program$369,564
R25 · FY2025 · CA · contact PI
Colorado Preparation in Interdisciplinary Knowledge to Excel PREP$325,466
R25 · FY2025 · GM · contact PI
Cell Immunotherapy and Experimental Therapeutics Program (CIETP).$227,238
T32 · FY2025 · CA
Expanding the tumor antigen landscape and maintaining APCs in a T cell-activating state to restore tumor immunity$449,997
R01 · FY2024 · CA · contact PI
Colorado Preparation in Interdisciplinary Knowledge to Excel PREP$325,466
R25 · FY2024 · GM · contact PI
Restoring the Regulation of a Central Signaling Pathway to Prevent Metastases and Reinstate Tumor Immunity$0
I01 · FY2024 · VA · contact PI
Expanding the tumor antigen landscape and maintaining APCs in a T cell-activating state to restore tumor immunity$447,162
R01 · FY2023 · CA · contact PI
Colorado Preparation in Interdisciplinary Knowledge to Excel PREP$325,466
R25 · FY2023 · GM · contact PI
Cancer Immunotherapy and Experimental Therapeutics - T32$130,419
T32 · FY2023 · CA
Restoring the Regulation of a Central Signaling Pathway to Prevent Metastases and Reinstate Tumor Immunity$0
I01 · FY2023 · VA · contact PI
Colorado Preparation in Interdisciplinary Knowledge to Excel PREP$325,466
R25 · FY2022 · GM · contact PI
Cancer Immunotherapy and Experimental Therapeutics - T32$286,113
T32 · FY2022 · CA
Restoring the Regulation of a Central Signaling Pathway to Prevent Metastases and Reinstate Tumor Immunity$0
I01 · FY2022 · VA · contact PI
Augmenting T cell activity to weak tumor antigens and reversing myeloid cell-mediated T cell inhibition$366,484
R01 · FY2021 · CA · contact PI
Cancer Immunotherapy and Experimental Therapeutics - T32$315,418
T32 · FY2021 · CA
Restoring the Regulation of a Central Signaling Pathway to Prevent Metastases and Reinstate Tumor Immunity$0
I01 · FY2021 · VA · contact PI
Augmenting T cell activity to weak tumor antigens and reversing myeloid cell-mediated T cell inhibition$366,484
R01 · FY2020 · CA · contact PI
Cancer Immunotherapy and Experimental Therapeutics - T32$345,257
T32 · FY2020 · CA
Restoring the Regulation of a Central Signaling Pathway to Prevent Metastases and Reinstate Tumor Immunity$0
I01 · FY2020 · VA · contact PI
Augmenting T cell activity to weak tumor antigens and reversing myeloid cell-mediated T cell inhibition$355,489
R01 · FY2019 · CA · contact PI
Cancer Immunotherapy and Experimental Therapeutics - T32$175,760
T32 · FY2019 · CA
IL-1 Receptor-Associated Kinase as a Cancer Therapeutic Target$0
I01 · FY2019 · VA · contact PI
Augmenting T cell activity to weak tumor antigens and reversing myeloid cell-mediated T cell inhibition$355,237
R01 · FY2018 · CA · contact PI
Augmenting T cell activity to weak tumor antigens and reversing myeloid cell-mediated T cell inhibition$57,393
R01 · FY2018 · CA · contact PI
IL-1 Receptor-Associated Kinase as a Cancer Therapeutic Target$0
I01 · FY2018 · VA · contact PI
IL-1 Receptor-Associated Kinase as a Cancer Therapeutic Target$0
I01 · FY2018 · VA · contact PI
Augmenting T cell activity to weak tumor antigens and reversing myeloid cell-mediated T cell inhibition$363,833
R01 · FY2017 · CA · contact PI
UMB Postbaccalaureate Research Education Program$283,321
R25 · FY2017 · GM · contact PI
IL-1 Receptor-Associated Kinase as a Cancer Therapeutic Target$0
I01 · FY2017 · VA · contact PI
UMB Postbaccalaureate Research Education Program$284,941
R25 · FY2016 · GM · contact PI
Tumor Immunology and Immunotherapy (TII)$125,542
P30 · FY2016 · CA · contact PI
IL-1 Receptor-Associated Kinase as a Cancer Therapeutic Target$0
I01 · FY2016 · VA · contact PI
IL-1 Receptor-Associated Kinase as a Cancer Therapeutic Target$0
I01 · FY2015 · VA · contact PI
Adoptive transfer of gene-modified autologous T-cells post-ASCT for myeloma$315,497
R01 · FY2014 · CA
Adoptive transfer of gene-modified autologous T-cells post-ASCT for myeloma$305,741
R01 · FY2013 · CA
TLR2 Engagement on Tumor-Specific T Cells: Mechanisms of Costimulation$270,208
R01 · FY2013 · CA · contact PI
TLR2 Engagement on Tumor-Specific T Cells: Mechanisms of Costimulation$290,273
R01 · FY2012 · CA · contact PI
TLR2 Engagement on Tumor-Specific T Cells: Mechanisms of Costimulation$293,119
R01 · FY2011 · CA · contact PI
TLR2 Engagement on Tumor-Specific T Cells: Mechanisms of Costimulation$311,250
R01 · FY2010 · CA · contact PI
MANIPULATION OF LYMPHOCYTE HOMEOSTASIS ENHANCING ANTI-TUMOR IMMUNITY$172,755
P20 · FY2010 · RR · contact PI
TLR2 Engagement on Tumor-Specific T Cells: Mechanisms of Costimulation$294,650
R01 · FY2009 · CA · contact PI
MANIPULATION OF LYMPHOCYTE HOMEOSTASIS ENHANCING ANTI-TUMOR IMMUNITY$198,775
P20 · FY2009 · RR · contact PI
MANIPULATION OF LYMPHOCYTE HOMEOSTASIS ENHANCING ANTI-TUMOR IMMUNITY$139,477
P20 · FY2008 · RR · contact PI
LSUHSC COBRE:PROJ 5:MANIPUL*OF LYMPHOCYTE HOMEOST* ENHANC* ANTI-TUMOR IMMUNITY$143,300
P20 · FY2007 · RR · contact PI
LSUHSC COBRE:PROJ 5:MANIPUL*OF LYMPHOCYTE HOMEOST* ENHANC* ANTI-TUMOR IMMUNITY$197,595
P20 · FY2006 · RR · contact PI
LSUHSC COBRE:PROJ 5:MANIPULATION/LYMPHOCYTE HOMOSTASIS$201,301
P20 · FY2005 · RR